All 3,282,994 Page 16/328,300
-
2025
Objectives: This study aimed to evaluate the imaging and clinical characteristics of adrenal metastases detected by [68Ga]Ga-PSMA PET/CT in prostate cancer patients, with a focus on diagnostic accuracy and prognostic implications. Specifically, we examined the correlation between adrenal lesion characteristics and prognostic markers, such as prostate-specific antigen (PSA) levels and Gleason scores. This study also assessed the diagnostic performance of PSA, standardized uptake value maximum (SUVmax), and Hounsfield Unit (HU) values in differentiating adrenal metastases from benign adrenal adenomas. Materials and Methods: This retrospective study included 44 prostate cancer patients with adrenal lesions identified using [68Ga]Ga-PSMA PET/CT between January 2020 and October 2024. The patients were categorized into two groups: benign adrenal adenomas (n = 16) and adrenal metastases (n = 28). The PET/CT imaging was performed using a 5-ring Discovery IQ PET/CT scanner with QClear reconstruction, following the injection of 2.5 MBq/kg [68Ga]Ga-PSMA ligand and a standardized uptake time of 60 min. The imaging parameters (SUVmax and HU values), clinical characteristics (PSA levels, Gleason scores, and presence of lymphadenopathy), and patient outcomes were analyzed. A ROC analysis was conducted to evaluate the diagnostic performance of these key parameters. Results: Patients with adrenal metastases had significantly higher PSA levels (mean: 45.6 ± 12.4 ng/mL vs. 18.3 ± 6.7 ng/mL; p < 0.01) and Gleason scores (median: 8 vs. 6; p < 0.01) than those with benign adenomas. SUVmax values were significantly elevated in metastatic lesions (mean: 12.8 ± 4.3 vs. 3.4 ± 1.2; p < 0.001), and HU values were also higher (mean: 45 ± 15 vs. 18 ± 10; p < 0.01). The ROC analysis revealed that SUVmax had the highest diagnostic accuracy (AUC: 0.87), followed by PSA (AUC: 0.85) and HU (AUC: 0.80). Disease progression was observed in 67.9% of metastatic cases versus 18.8% in the adenoma group (p < 0.001), and median overall survival was shorter in metastatic cases (24 months vs. 38 months; p < 0.01). Conclusions: [68Ga]Ga-PSMA PET/CT is a valuable imaging modality for distinguishing adrenal metastases from benign adenomas in prostate cancer patients. The integration of PSA, SUVmax, and HU values into diagnostic workflows enhances diagnostic precision and improves clinical decision-making. Future research should focus on the prospective validation of these findings in larger cohorts and explore artificial intelligence-based approaches for automated lesion characterization.- Book : 32(3)
- Pub. Date : 2025
- Page : pp.127-127
- Keyword :
-
2025
This study investigates the clinical efficacy of MRI-based adaptive brachytherapy (IGABT) using combined intracavitary and interstitial techniques in the curative treatment of patients with advanced cervical cancer (LACC). A retrospective analysis was conducted on 149 LACC patients treated at a single center. The therapeutic protocol included intensity-modulated external beam radiotherapy (IMRT) and IGABT. Dosimetric parameters were evaluated for relevance for local control (LC), progression-free survival (PFS), and overall survival (OS) using Kaplan–Meier estimation, Cox regression, and log-rank test. Patients predominantly presented with stage III/IV tumors (81%, FIGO 2018). The median high-risk clinical target volume (hrCTV) was 34 cm3, with a median D90% dose of 88.9 GyEQD2. At 24 months, OS, PFS, and LC rates were 86%, 57%, and 81%, respectively. FIGO stage, tumor volume, and histology were significant predictors of PFS. Higher total hrCTV doses were strongly correlated with improved LC and PFS, emphasizing the importance of precise dosimetric optimization in IGABT and confirming the critical role of IGABT in achieving very good LC rates for LACC. The reported LC rates are comparable to landmark studies, such as INTERLACE and KEYNOTE-A18. This study validates the effectiveness of MRI-guided IGABT in enhancing local tumor control in advanced-stage cervical cancer while providing insights into the prognostic implications of dosimetric parameters such as hrCTV and point A. Future research should address the persistent challenge of distant metastases by exploring the integration of novel systemic treatment options.- Book : 32(3)
- Pub. Date : 2025
- Page : pp.136-136
- Keyword :
-
2025
- Book : ()
- Pub. Date : 2025
- Page :
- Keyword :
-
2025
- Book : ()
- Pub. Date : 2025
- Page :
- Keyword :
-
2025
- Book : ()
- Pub. Date : 2025
- Page :
- Keyword :
-
2025
- Book : ()
- Pub. Date : 2025
- Page :
- Keyword :
-
2025
- Book : ()
- Pub. Date : 2025
- Page :
- Keyword :
-
2025
AbstractNew anodic electrocatalysts with high performance and cost‐effectiveness at large current densities help advance the emerging anion exchange membrane water electrolyzer (AEMWE) technology. To this end, a ruthenium (Ru) single atoms and sulfur (S) anions dual‐doped NiFe layered double hydroxides (Ru‐S‐NiFe LDH) catalyst is reported with remarkably low alkaline oxygen evolution reaction (OER) overpotentials, high mass activities and prolonged stabilities at high current densities. Inspiringly, the AEMWE performance on Ru‐S‐NiFe LDH is also superior to the NiFe LDH. In‐depth mechanism investigations reveal that Ru single atoms not only act as the highly active sites, but also facilitate the conductivity of NiFe LDH. Meanwhile, S anions accelerate the electrochemical reconstruction of NiFe LDH to OER‐active NiFeOOH and alleviate the over‐oxidation issue on Ru active sites. Benefiting from these, Ru‐S‐NiFe LDH shows significantly enhanced OER activity and stability. Theoretical calculations further validate the decreased OER free energy difference brought about by the Ru single atoms and S anions dual‐doping. This study offers a proof‐of‐concept that the noble metal single atoms and anions dual‐doping is a feasible strategy to construct the promising 3d transition metal‐based electrocatalysts toward the practical alkaline water electrolyzer.- Book : ()
- Pub. Date : 2025
- Page :
- Keyword :
-
2025
- Book : ()
- Pub. Date : 2025
- Page :
- Keyword :
-
2025
- Book : ()
- Pub. Date : 2025
- Page :
- Keyword :
